PomegraInovio Stock Soars 214% After FDA Approval of Voceryq
Why did Inovio stock jump 214%?
Inovio (INO) stock soared 214% to $1.89 on Monday after the FDA granted accelerated approval to Voceryq, its first product and the first US-approved plasmid DNA immunotherapy.
Key numbers
| Inovio close, Nov 2 | $1.89+214% vs prior close |
|---|---|
| Early-session gain | +187%widened to +214% by close |
| No surgery for 12 months | 27%7 of 26 patients |
| Precigen shares | -26%after rival's approval |
| Expected price (per [5]) | $115,000per dose, four-dose course |
What happened
Inovio (INO) stock soared 214% to $1.89 on Monday after the FDA granted accelerated approval to Voceryq, its first product and the first US-approved plasmid DNA immunotherapy. Voceryq treats recurrent respiratory papillomatosis (RRP), a rare disease where airway growths keep returning and need surgery. In a study, 7 of 26 patients (27%) needed no surgery for 12 months after treatment. Approval is conditional on a follow-up study, and shipping should start in about 60 days. Rival Precigen, which sells a competing RRP treatment, fell about 26%.
Why it matters
Inovio is a small company that now has its first approved product, which could change its finances after years of trading near lows. Voceryq is also the first US-approved medicine of its kind built on DNA. Patients with RRP gain another option, but its 27% surgery-free rate trails the 51% reported for Precigen's Papzimeos in separate trials, and the approval depends on a confirmatory study.
Who this affects
- MarketneutralLow impact
- Small biotech traders cheered; the wider market barely moved.
- CompanybullishHigh impact
- Inovio shareholders gain; its first product now has FDA clearance.
- CompetitorsbearishHigh impact
- Precigen investors lose; its treatment now faces a new rival.
- IndustrybullishMedium impact
- DNA-medicine developers gain a first US approval precedent.
Inovio vs Precigen
How we got here
FDA grants accelerated approval to Voceryq; Inovio announces first approved DNA medicine.
Inovio shares close up 214% at $1.89 on heavy trading.
Precigen shares fall about 26% as its rival RRP treatment is cleared.
What to watch
- Precigen reports third-quarter results, its first update since Voceryq's approval (date per)2026-11-04
- Inovio must send the FDA a draft confirmatory study protocol to keep approval2026-12-31
- Full field deployment of Voceryq, after orders open in about 60 daysQ1 2027
Educational content only. Not investment advice.
More briefsAll briefs →
Alibaba Stock Rises 3.5% After Apple Picks Qwen AI for China
Alibaba (BABA) closed at $101.50 while Hong Kong's tech index gained 2.25% after a rough October.
Australia Cash Rate Rises to 4.85% as Inflation Climbs
The Reserve Bank of Australia (RBA) split 6–3 on its fifth 2026 hike as yearly inflation hit 4.3%.
Amazon Stock Rises 2.2% on Analyst Upgrade
Amazon (AMZN) briefly gained 5% as Phillip Securities lifted its price target to $330 on cloud strength